|
Xyotax?
FDA recently fast-tracked this taxane for use against lung cancer. It made more of a difference in women than men, and the reason had something to do with estrogen. Don't know how it is for neuropathy. You'd have to check the phase I trials.
Another taxane in the pipeline is taxoprexin, which had much less neuropathy in phase I because it is really targeted (due to the clever use attachment of DHA, the fish oil, as bait for the cancer). This is in the pipeliene to be fast-tracked for malignant melanoma, but I don't think it is through yet.
|